

Elevator Pitch: LiveLunger

Name Start-up Company : LiveLunger

Name (co-)Founder: Veerle De Colvenaer

Mission Statement: Through revolutionizing respiratory care, we unlock the potential for patients to stay within control at home.



About Us:

LiveLunger creates groundbreaking products that transform respiratory care. We've created LungBeat: a clinically validated telemonitoring solution empowering chronic asthma patients in their daily asthma self-management.

Problem aiming to solve:

Asthma is a major noncommunicable disease, affecting both children and adults, being the most common chronic disease among children. Worldwide 262M people are affected by asthma. On average 1000 people die globally from asthma each day. Although efficient medication exists for asthma patients, deterioration of patient's conditions is often due to one of the following factors: (1) Patients do not adhere to their therapy plan; (2) Patients do not apply their medication in a correct way; (3) HCP do not have sufficient insights in the patients' condition in-between consultations and the severity of asthma is not correctly estimated; (4) It takes too long to achieve a status of asthma control because of the long period in between consultations. Moreover, asthma is a heterogenous condition, influenced by many comorbidities, which requires a close and personalized follow up.

Our Solution:

Our CE-Class I certified solution, LungBeat is composed out of a mobile app and a Bluetooth connected

spirometer to be used by the patient at-home; and a web portal for the lungnurse or pulmonologist in the healthcare setting. The mobile app enables the patients to do a quick check of their asthma status at home. Through a weekly questionnaire of 7 questions a weekly check of their status formulates a weekly advice on their therapy. This questionnaire is supplemented by the measurement of the lung capacity (FEV1 is the volume of air that can forcibly be blown out in first 1-second after full inspiration). The combined score of the questionnaire and the FEV1 spirometry value is crosschecked against the personalized action plan, which has been uploaded by the healthcare professional into the webportal of LungBeat.

USP:

The value of LungBeat was validated in clinical trials, showing improved asthma control, improved medication adherence and reduced risk for exacerbations. We are available in 11 languages. We were graded easy to use by patients. We offer a unique solution of a lungnurse-as-a-service on-site in the hospitals to lower the burden for clinicians.

Seeking:

To further internationalize we seek additional funding. Moreover we seek collaborators to build our next product that will not only monitor patients, but will also predict their risk at deterioration.

Start-up & Scale-up **NEWS**

Azafaros announces Oversubscribed €132M Series B Financing to Advance Phase 3 Clinical programs of innovative therapies in lysosomal storage disorders.

CryoCloud raises €2M to enhance machine learning for drug discovery.

Agomab announced positive topline Phase 2a interim results for AGMB-129 in Fibrostenosing Crohn's Disease.

Avidicure emerges from stealth with \$50M seed round.

Alesta Therapeutics raised €65M in Series A to develop a treatment for hypophosphatasia, a rare genetic disease that weakens bones, teeth and muscles.

CurieGen raised €2.2M in a pre-seed round to redefine drug discovery through AI-powered single-cell multi-omics.

Doderm secures high six-figure funding to drive innovation in skin health.

Augustine Therapeutics raises €78 million to start clinical trials with its HDAC6 inhibitor.

EvidenceHunt raises €1.2 million for processing medical-scientific data into actionable insights.

TargED Biopharmaceuticals enters clinic with Phase 1 trial of its groundbreaking thrombolytic TGD001 to assess TGD001's safety and tolerability in healthy volunteers.

TigaTx has been awarded up to \$33.5 million in funding by the Advanced Research Projects Agency for Health (ARPA-H).

Sirius Medical raised 10 M EUR in scale-up funding to enhance the Pintuition Surgical Marker Navigation platform and extend their global reach to new markets.

BIMINI Biotech raised a EUR3M seed round to advance first-in-class therapeutics for hematological cancers.

Leyden Labs raised \$70M to Advance its Intranasal Antibody Programs to Protect against Influenza and other Viruses.

Citryll raised EUR 85 million Series B to Advance Novel Net-Targeting Therapy for Immune-Mediated Inflammatory Disorders.

Synaffix has entered into an exclusive #ADC license agreement with Boehringer Ingelheim worth over \$1.3 billion.